Healthcare Industry News: Synta Pharmaceuticals
News Release - July 12, 2006
AAIPharma Announces Appointment of Vice President of Pharmaceutical Business DevelopmentWILMINGTON, N.C.--(HSMN NewsFeed)--July 12, 2006--AAIPharma Inc. announced today the appointment of Ninad Deshpanday, Ph.D. to the newly created position of Vice President of Pharmaceutical Business Development. In this role, Dr. Deshpanday will be responsible for all North American business development activities in Pharmaceutical Development, including Analytical, Biotechnology, Formulations Development, GMP Manufacturing and Clinical Trial Materials for both Oral and Parenteral dosage forms.
Dr. Deshpanday brings to AAIPharma over fifteen years experience in pharmaceutical development. Prior to joining the Company, he was Vice President of Drug Product Development for Synta Pharmaceuticals, with responsibilities for all CM&C activities. Prior to this, he served Cardinal Health as Technical Business Director for the Pharmaceutics division. Previously, Dr. Deshpanday held leadership positions at AAIPharma, including Senior Manager of Formulations Development and Global Product Director of Pharmaceutics.
"Dr. Deshpanday possesses a unique combination of leadership skills and technical expertise in pharmaceutical development, and is a great addition to our business development team," stated Pete Megronigle, Senior Vice President of North American Business Development. "This appointment represents AAIPharma's continued focus on maximizing technical capabilities with regional effectiveness and broadening its position in the marketplace."
AAIPharma Inc. is a global provider of product development and support services to the pharmaceutical, biotechnology, and medical device industries. From a single test through a range of integrated service offerings, we create value to an industry in search of productivity and innovation. For more information on the Company, please visit AAIPharma's website at www.aaipharma.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.